The articles listed on this page are from a variety of sources. 
1. The staff of DBS-STN often attends conferences or educational opportunities both nationally and internationally, and a brief understandable write-up of the information presented at the event will be provided for our readers to review. 
2. DBS-STN staff also identifies or writes various articles related to topics that are thought to be of interest for the reader of www.DBS-STN.org. 

Browse by Topic:
Search:

Adamas Announces US FDA Acceptance of ADS-5102 New Drug Application for the Treatment of Levodopa-induced Dyskinesia in Patients with PD


(January 6, 2017) - Adamas Pharmaceuticals announced that the U.S. Food and Drug Administration has accepted for review the New Drug Application for ADS-5102 (amantadine hydrochloride) extended-release capsules, for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. If approved, ADS-5102 will be the first and only medicine approved for the treatment of LID in Parkinson’s disease. Read more



Article Archive

back